What is Monte Rosa Therapeutics, Inc.'s EBITDA margin?

Monte Rosa Therapeutics, Inc. (GLUE) reported EBITDA margin of -325.8% in Q1 2026.

What does EBITDA margin mean?

EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.

Monte Rosa Therapeutics, Inc. GLUE EBITDA margin

EBITDA margin at other companies

Bristol-Myers SquibbBMY

27.2%-2.2pp

Nurix Therapeutics, Inc.NRIX

-427.3%+42.6pp

Kymera TherapeuticsKYMR

-681.6%+642pp

ImmunomeIMNM

-5,886.7%-11,897pp

Adaptive BiotechnologiesADPT

-10.1%-4.6pp

Arcus BiosciencesRCUS

-164.8%-51.5pp

Other financials

Income statement

See full

Revenue$4.2M-95.0%

Operating income-$50.0M-214%

Net income-$44.5M-195%

EPS (diluted)-$0.45-179%

Balance sheet

See full

Cash & equivalents$159.9M+104%

Total debt$39.1M-6.7%

Total equity$521.9M+89.7%

Total assets$736.4M+87.3%

Cash flow

See full

Operating cash flow-$37.4M+17.9%

CapEx$1.9M+17.7%

Free cash flow-$39.2M+16.7%

Valuation

See full

Market cap$1.75B+361%

Enterprise value$1.63B+381%

P/S40.7×+38.4×

Profitability

See full

Operating margin-345.2%—

Net margin-302.6%—

FCF margin-45.8%-64.9pp

Returns & leverage

See full

Return on equity-32.6%—

Debt / equity0.1×-0.1×

Current ratio9.5×+3.9×

Where this comes from

Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.

ebitda/total revenue=-325.8%

Based on trailing twelve months.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s EBITDA margin?: Monte Rosa Therapeutics, Inc. (GLUE) reported EBITDA margin of -325.8% in Q1 2026.
What does EBITDA margin mean?: EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.